Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-12
2006-09-12
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07105489
ABSTRACT:
The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
REFERENCES:
patent: 6329403 (2001-12-01), Odaka et al.
patent: 2004/0180824 (2004-09-01), Knudsen
Stephen Franks, M.D., “Polycystic Ovary Syndrome”,Medical Progress, vol. 333, No. 13, p. 853-861, Reproductive Endocrinology Group, Department of Obstetrics and Gynecology, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, University of London, London W2 IPG, United Kingdom (1995).
Robert L. Barbieri, MD, “Induction Of ovulation in Infertile Women With Hyperandrogenism And Insulin Resistance”,Am J. Obstet Gynecol, 2000; 183:1412-8, Copyright 2002 by Mosby, Inc., From the Department of Obstetrics,Gynecologyand Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, p. 1412-1418.
Laurence Udoff and Eli Y. Adashi, “Polycystic ovarian disease: a new look at an old subject”,Current Opinion in Obstetrics and Gynecology, 1995, 7:340-343, Rapid Science Publishers ISSN 1040-872X, Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Lena H. Kim, M.D., Ann E Taylor, M.D. and Robert L. Barbieri, M.D.,Fertility And Sterility, vol. 73. No. 6, Jun. 2000, “Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?”, vol. 73, No. 6, Jun. 2000, Copyright 2000 American Society for Reproductive Medicine, Published by Rapid Science Printed USA, pp. 1097-1098.
Joffe Hadine, Ann E. Taylor and Janet E. Hall, “Editorial: Pelycystic Ovarian Syndrome—Relationship to Epilepsy and Antiepileptic Drug Therapy”,The Journal of Clincal Endocrinology&Metabolism, Copyright 2001 by the Endocrine Society, vol. 86, No. 7, Women's Center for Behavioral Endocrinology, McLean Hospital (H.J.) Belmont, Mass, pp. 2946-2949.
Maria J. Iuorno, M.D. and John E. Nestler, M.D.,Obstetrics and Gynecology Clinics of North America, “Insulin-Lowering Drugs in Polycystic Ovary Syndrome”, vol. 28, No. 1, Mar. 2001, Department of Medicine, Division of Endocrinology and Metabolism, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA., pp. 153-164.
Howard A. Zachur, “Polycystic Ovary Syndrome, Hyperandrogenism, and Insulin Resistance”,Obstetrics and Gynecology Clinics of North America, vol. 28, No. 1, Mar. 2001, Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, pp. 21-33.
William R. Phipps, M.D., “Polycystic Ovary Syndrome and Ovulation Induction”,Obstetrics and Gynecology Clinics of North America, vol. 28, No. 1, Mar. 2001, Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York, pp. 165-182.
Lynda J. Wolf, M.D., “Ovulation Induction”,Clinical Obstetrics and Gynecology, vol. 43, No. 4, pp. 902-915, Copyright 2000, Lippincott Williams & Wilkins, Inc.
Adam Balen, “Ovulation Induction for polycystic ovary syndrome”,Human Fertility, 2000, 3, 106-111, Department of Reproductive Medicine, The General Infirmary, Copyright The British Fertility Society, Leeds LS2 9NS, UK, 1464-7273/2000.
Gerard S. Conway, “Hyperinsulinaemia and polycystic ovary syndrome”,Human Fertility(2000) 3, 93-95, 2000 The British Fertility Society 1464-7273/2000.
Bridget Lieser Ahles, M.D., “Toward a New Approach: Primary and Preventive Care of the Woman With Polycystic Ovarian Syndrome”,Primary Care Update OB/Gyns 2000; 7: 275-278, Copyright 2000 Elsevier Science, Inc. (PII S 1068-607X(00)00059-7.
Richard S. Legro, M.D., “Polycystic ovary syndrome: Current and future treatment”,Am J. Obstet Gynecol 1998, 179:S101-8) Copyright 1998 by Mosby, Inc.
M. Ciampelli and A. Lanzone, “Insulin and polycystic ovary syndrome: a new look at an old subject”,Gynecol Endocrino1998; 12:277-292; Department of Obstetrics and Gynecology, Catholic University of Sacred Heart, Rome, Italy; and *OASI Institute for Research, Troina (EN), Italy.
Rina M. Davison, “New approaches to insulin resistance in polycystic ovarian syndrome”,Current Opinion in Obstetrics and Gynecology1998, 10:193-198; Division of Endocrinology, Department of Medicine, University College London, School of Medicine, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK; 1998 Lippincott-Raven Publishers.
Bruce M. Spiegelman, “PPARy in Monocytes: Less Pain, Any Gain?”,Cell, vol. 93, 153-155, Apr. 17, 1998, Copyright 1998 by Cell Press.
Jerrold M. Olefsky and Alan R. Saltiel, “PPARy and the Treatment of Insulin Resistance”,TEM, vol. 11, pp. 362-367, No. 9, 2000. 2000 Elsevier Science Ltd.
Michel Pugeat and Pierre Henri Ducluzeau, “Insulin Resistance, Polycystic Ovary Syndrome and Metformin”,Drugs, 1999 58 Suppl. 1:41-46, Adis International Limited.
Stephen Franks, M.D., FRCP, HON MD (Uppsala), Carole Gilling-Smith, PhD, MRCOG, Hazel Watson, BSc, MSc, and Debbie Willis, PhD, “Insulin Action in the Nomal and Polycystic Ovary”,Endocrinology And Metabolism Clinics Of North America, vol. 28, No. 2, Jun. 1999, pp. 361-378, Department of Reproductive Science and Medicine, Imperial College School of Medicine, St. Mary's Hospital; and the Assisted Conception Unit, Chelsea & Westminster Hospital, London, UK.
Robert L. Rosenfield, M.D., “Current Concepts of Polycystic Ovary Syndrome”,Bailliere's clinical Obstetrics and Gynaecology, vol. 11, No. 2, Jun. 1997, pp. 306-332, Copyright 1997, by Bailliere Tindall.
Zoe E. C Hopkinson, Naveed Sattar, Richard Fleming, Ian A Greer, “Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology”, vol. 11, No. 2, Jun. 1997, pp. 329-332,BMJ, vol. 317, Aug. 1, 1998.
David A. Ehrmann, M.D., “Relation of functional ovarian Hyperandrogenism to non-insulin dependent diabetes mellitus”,Vailliere's Clinical Obstetrics and Gynaecology, vol. 11, No. 2, Jun. 1997, 335-346; Copyright 1997 by Bailliere Tindall.
John E. Nestler, M.D., “Role of Hyperinsulinemia in the Patho9genesis of the Polycystic Ovary Syndrome, and Its Clinical Implications”,Seminars in Reproductive Endocrinology, vol. 15, No. 2, May 1997, pp. 111-122, Copyright 1997 by Thieme Medical Publishers, Inc.
Robert D. Utiger, M.D.,The New England Journal of Medicine, pp. 657-658, Aug. 29, 1996, 1996 Massachusetts Medical Society.
Amylin Pharmaceuticals Inc.
Russel Jeffrey Edwin
LandOfFree
Methods and compositions for treating polycystic ovary syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating polycystic ovary syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating polycystic ovary syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543481